On January 4, 2022, Uni-Bio Science Group and Global Cosmetics reach a strategic cooperation to jointly develop new competitive and effective skincare raw materials, to be used widely in a variety of areas including medical cosmetology, functional skincare and high-end skincare.

On 2nd Sep 2021,Uni-Bio Science Group Limited is pleased to announce that the company collaborates with Nano and Advanced Materials Institute (NAMI) to explore an innovative formulation of rEGF (Recombinant human Epidermal Growth Factor) products including Genetime® .

On 1st Sep 2021,Uni-Bio Science Group Limited is pleased to announce that the company has formed a strategic alliance with Alephoson Biopharmaceuticals Ltd. (“Alephoson”) to explore the use of Cell Penetration Protein Alternation Technology (CePPA) with the Group’s next generation, best-in-class compounds for patients with retinal diseases and other potential therapeutic areas. The partnership will involve a close collaboration between the two companies.

On 10th March 2021,Uni-Bio Science Group Limited is pleased to announce that the company and DotBio Pte. Ltd. (“DotBio”) formed a partnership to co-develop next generation, best-in-class therapeutics for patients with retinal diseases, such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). These diseases are major causes of visual impairment and blindness worldwide.

On 14th May 2020, Uni-Bio Science Group Limited reached a strategic partnership with Chengdu Medlinker Technology Company Limited (Medlink), to further develop digital marketing channels for the Uni-Bio’s products, and to expand industry value chain downstream to pharmaceutical E-commerce. According to the agreement, both companies will start working on Genetime®, expanding its marketing channel to dermatology related clinical experts, and will collaborate across several verticals, including smart healthcare, disease management, patient and clinical practitioner education, academic marketing, healthcare big data, and drug tracing system, to create an integrated healthcare offering.

To offer more convenient healthcare solution for clinical practitioners and patients, Uni-Bio collaborates with a Switzerland company Ypsomed to develop Uni-Bio products with prefilled injection pen YpsoPen. According to the agreement, the Ypsomed will design YpsoPen for the group’s pipeline products Uni-E4 and Uni-PTH, and Beijing Genetech Pharmaceutical (a wholly owned subsidiary of Uni-Bio) will be responsible for the clinical development afterwards. The collaboration does not only greatly enhance the competitiveness of both products, but also pave a way for both parties to develop additional innovative products based on Ypsomed’s market leading self-care solution platform.

On 15th April 2020, Beijing Genetech Pharmaceutical Company Limited (Beijing BKJ), a wholly-owned subsidiary of Uni-Bio Science Group Limited, formed a strategic partnership with Sinopharm Weiqida Pharmaceutical Company Limited (Sinopharm Weiqida ) and Suzhou Yingli Medical Technology Company Limited (Suzhou Yingli) to improve the industry value chain for the Group product Acarbose (also known as“Boshutai”). According to the agreement, Suzhou Yingli is responsible for the early development of Acarbose active ingredient, Sinopharm Weiqida is responsible for Acarbose API industrialization development, manufacturing and supply, and as a result, Beijing BKJ will have at least 10 years stable supply of Acarbose API for product commercialization.

On 5th Jun 2018, Beijing Genetech Pharmaceutical Co., Limited (a wholly-owned subsidiary of Uni-Bio Science Group Limited) and Beijing Baiao Pharmaceutical Co., Ltd. (“Beijing Baiao Pharmaceutical”) entered into a strategic cooperation agreement on the joint development and promotional marketing of Acarbose tablets project. Beijing Baiao Pharmaceutical will invest to acquire interests in Acarbose tablets products and be entitled to future marketing profit. The relevant expenses on project research shall be borne by both parties. Meanwhile, as a marketing authorization holder, the Group shall be responsible for the management of pre-launch declaration and registration and the arrangement of post-launch production and sales, while Beijing Baiao Pharmaceutical shall be responsible for the post-launch promotion of the products in the markets of designated provinces.

On 1st Dec 2016, Beijing Genetech, subsidiary of Uni-Bio Science Group entered into a strategic agreement to co-develop promising oral anti-diabetic drugs (OAD). Acarbose will be the first product developed together, both companies will explore development of another 2 to 3 OAD. Sun-Novo has strong development track record in China with 65 IND approvals, 2 NDA approvals for API, 2 NDA approvals for finished drug.